Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Distribution, selling, general and administrative expenses

Restructuring and employee severance

Amortization and other acquisition-related costs

Impairments and (gain)/loss on disposal of assets, net

Litigation (recoveries)/charges, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Cardinal Health

Cordis develops and manufactures medical devices for diagnostics and interventional procedures to treat patients suffering from coronary and peripheral vascular diseases.On October 4, 2015, Cardinal Health announced that it has completed the acquisition of Johnson & Johnson's Cordis business for $1.944 billion.

Cordis

Cardinal Health, Inc. is a healthcare services and products company, which engages in the provision of customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, and physician offices. It also provides medical products and pharmaceuticals and cost-effective solutions that enhance supply chain efficiency. The firm operates through the Pharmaceutical and Medical segments. The Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical and over-the-counter healthcare and consumer products. The Medical segment manufactures, sources and distributes Cardinal Health branded medical, surgical, and laboratory products. The company was founded by Robert D. Walter in 1979 and is headquartered in Dublin, OH.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Cardinal Health reports strong Q3 results, focuses on Pharma growth

Cardinal Health's Q3 results demonstrated strong performance in the Pharma segment, while the Medical segment faced challenges. The company raised its guidance for the year and emphasized the importance of Red Oak Sourcing in maintaining market dynamics. Looking ahead, the company is focused on executing its medical improvement plan and maximizing shareholder value.

Cardinal Health reports stable Q2 growth, eyes Pharma segment

Cardinal Health's Q2 2023 performance showcased stability and growth in the Pharma segment, with a return to profitability in the Medical segment.
The company's strategic focus on executing key priorities and driving shareholder value creation is evident in its financial results.
Challenges such as international freight costs and supply chain headwinds are being addressed, while opportunities in COVID therapies, pricing strategy, and growth investments are being pursued.
Overall, Cardinal Health's revised outlook and strong performance in key segments position it for continued growth and financial success.

Cardinal Health reports robust Q3 earnings, eyes biosimilars for growth

Cardinal Health delivered strong financial performance in Q3 2023, driven by robust growth in the Pharma segment.
While facing challenges in the Medical segment, the company remains focused on mitigating inflation and maximizing shareholder value.
With a positive outlook on future growth opportunities, Cardinal Health aims to address cost pressures and drive profitability.

Cardinal Health achieves record results, raises guidance for fiscal '24

Cardinal Health's strong performance in Q4 and fiscal year 2023, coupled with strategic initiatives and guidance raise, position the company for continued growth and success.
Challenges such as inflation mitigation and cost pressures are being addressed, while opportunities in organic growth and strategic investments pave the way for future profitability.
The company's focus on advancing Pharma, executing the Medical Improvement Plan, and maximizing shareholder value creation underscores its commitment to sustained growth and value creation.

Cardinal Health reports strong Q1 earnings, raises guidance for FY24

Cardinal Health's Q1 2024 earnings call showcased robust performance, with profit growth in both Pharma and Medical segments. The company raised EPS guidance, demonstrated strong cash flow generation, and emphasized customer service and shareholder value creation. Challenges include managing margins, nonoperating items, and commodity price impacts, while opportunities lie in healthcare sector growth, innovation, and market dynamics.

Cardinal Health reports robust Q2 earnings, raises EPS guidance

Cardinal Health's Q2 performance reflects strong revenue growth, improved cash flow, and raised EPS guidance, supported by strategic acquisitions and growth initiatives.
While facing challenges from nonrecurring adjustments and SG&A growth, the company remains focused on core businesses and driving future growth opportunities.
With a positive outlook on market-driven growth, cost management, and strategic priorities, Cardinal Health aims to sustain its momentum and deliver value to shareholders.

Cardinal Health reports robust Q3 earnings, eyes growth opportunities ahead

Cardinal Health's Q3 performance reflects strong financial results and strategic progress across key segments, with raised guidance for fiscal '24 and '25.
The company faces challenges such as managing customer transitions and inflationary impacts but is well-positioned to capitalize on growth opportunities.
By focusing on cost optimization, strategic partnerships, and customer-centric solutions, Cardinal Health aims to drive sustained growth and profitability.
Investments in technology, brand growth, and operational efficiency underscore Cardinal Health's commitment to delivering value to shareholders and customers.

Cardinal Health excels in fiscal '24, raises guidance for '25

Cardinal Health's strong performance in fiscal year '24, highlighted by record financial results and strategic progress, positions the company for continued success.
Despite challenges such as market dynamics and customer transitions, the company's raised guidance for fiscal year '25 underscores confidence in future growth.
By capitalizing on strengths like revenue growth in key segments and making strategic investments, Cardinal Health is poised to navigate challenges and seize opportunities for sustained growth.

Cardinal Health reports strong Q1 performance and raises fiscal guidance

Cardinal Health's Q1 performance showed strength in Pharma and Specialty Solutions despite revenue decrease.
Challenges in GMPD segment and nuclear supply disruptions are being addressed for minimal impact.
Opportunities lie in continued cost reductions, growth normalization, and operational improvements.
Overall, Cardinal Health is well-positioned to navigate challenges and capitalize on growth opportunities.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Aflac

Procter & Gamble

During times of heightened volatility, an established income stream is undoubtedly a major positive, allowing investors to offset losses in other positions and reap those sweet dividend payouts.

Seeking Income? Consider These 3 Dividend Aristocrats

Launching a New, Robust Offering Leveraging Cardinal Health's Advanced Practice Analytics Technology Platform and PayrHealth's Payor Contracting Solution. AUSTIN, Texas , Sept.

PayrHealth Announces Collaboration with Cardinal Health

Apple

American Electric Power Company

Chevron

Iron Mountain

Keurig Dr Pepper Inc

Microsoft

NortonLifeLock

Oracle

Principal Financial Group

Philip Morris

UnitedHealth Group

Exxon Mobil

Tuesday's massive stock market meltdown should serve as a reminder to investors that in times of turmoil, it pays to own shares of companies that also pay you.

As markets wobble, buy the stocks that pay you back

Cardinal Health (CAH) projects Medical segment loss to be in the range of $25 million to $55 million for the first quarter of fiscal 2023, owing to inventory charges related to the company's gloves portfolio.

Cardinal Health (CAH) Lowers Medical Segment Income Guidance

Cardinal Health stock (NYSE: CAH) has seen a significant 36% rise this year, outperforming the broader S&P500 index, which is down 15%.

What's Happening With Cardinal Health Stock?

Cardinal Health Inc. CAH, -1.23% cut its fiscal first-quarter earnings outlook for its Medical segment, citing ongoing simplification efforts that are expected to result in $25 million in inventory charges related to its gloves portfolio. The company now expects a Medical segment loss of $55 million to $25 million, compared with a previous guidance range for a loss of $20 million to a profit of $20 million.

Cardinal Health cuts earnings outlook for Medical segment, sees $25 million in inventory charges

Cardinal Health recently entered an agreement with Elliott Management, agreeing to appoint four director nominees to the board.

A shake-up on Cardinal Health's board could pave the way for activist fund Elliott to create value

--Victor Crawford will step down as CEO of Pharmaceutical Segment-- --Debbie Weitzman, President of Pharmaceutical Distribution, named CEO of Pharmaceutical Segment-- DUBLIN, Ohio , Sept. 8, 2022 /PRNewswire/ -- Cardinal Health (NYSE: CAH) today announced Debbie Weitzman, current President of Pharmaceutical Distribution, will become CEO of the Company's Pharmaceutical Segment.

Cardinal Health Announces Pharmaceutical Segment Organizational Changes

The stock price of Cardinal Health (CAH) fell by 2.08% today. This is why.

Cardinal Health (CAH) Stock: Why It Fell 2.08% Today

Cardinal Health Inc. CAH, -0.46% announced a series of measures Tuesday aimed at boosting shareholder value and said activist investor Elliott Investment Management's Steven Barg will join its board. Among the moves, the medical products and services company will for a new Board committee to conduct a review of its strategy, portfolio, capital-allocation framework and operations.

Cardinal Health to form new board committee to review business as part of corporate governance moves agreed with Elliott

Adds Four New Independent Directors to the Board Forms New Business Review Committee to Evaluate Portfolio and Operations DUBLIN, Ohio , Sept. 6, 2022 /PRNewswire/ -- Cardinal Health (NYSE: CAH) today announced initiatives aimed at positioning the Company for long-term success, building on Cardinal Health's previously announced growth plans.

Cardinal Health Announces Governance Enhancements and Shareholder Value Creation Initiatives

Cisco Systems

Their payouts are likely to continue rising.

2 High-Yielding Dividend Stocks You Can Buy and Hold for Years

Ball Corp

Constellation Energy Corp

Catalent

DXC Technology

EPAM Systems

Match Group

Nielsen Hlds

SolarEdge Technologies

EPAM Systems was the best performer in the index in August. Ball Corp. was the worst.

The 5 Best and 5 Worst Performers in the S&P 500 in August

APA Corporation

Bristol-Myers

CF Industries Holdings

Diamondback Energy

Johnson & Johnson

Oil stocks were S&P 500 winners Monday, including Diamondback Energy. Bristol Myers Squibb was among the big losers.

S&P 500 Stock Market Winners Today

Archer-Daniels-Midland Company

Corteva Inc

Enphase Energy

Lamb Weston Hlds

McKesson

Mosaic

Vertex Pharmaceuticals

It's been almost all about energy stocks in the S&P 500 this year. But not entirely.

10 Stocks (Not In The Energy Sector) Are Up 30% Or More This Year

One of the U.S.'s three dominant drug-distribution companies, Cardinal Health, is in the crosshairs of an activist investor.

Failing in an Oligopoly Takes Serious Mismanagement

The shares of Cardinal Health Inc (NYSE:CAH) have been on quite a tear lately, up 26.7% in the last month, with only two negative days since July 19.

Cardinal Health Receives Bull Notes After Activist Investor News

Activist investor Elliott Management has a large position in Cardinal Health Inc. and is seeking a handful of seats on the medical-products distributor's board, according to people familiar with the matter.

Activist investor Elliott Management discloses large stake in Cardinal Health

The activist investor is seeking a handful of seats on the medical-products distributor's board, according to people familiar with the matter.

Elliott Management Has Large Position in Cardinal Health

Cincinnati Financial

Canadian Imperial Bank of Commerce

First Bancorp

Fulton Financial

Genuine Parts

GlaxoSmithKline

Huntington Bancshares

Haleon PLC

Illinois Tool Works

Leggett & Platt

Realty Income Corp

Orion Office REIT

Occidental Petroleum

Paramount Global

Schlumberger

TotalEnergies SE

Our total dividend income decreased from $771.96 received in July 2021. Canadian Imperial takes the crown for the largest dividend payment of the month.

Bert's July Dividend Income Summary | Dividend Investing 2022

Cardinal Health, Inc. (NYSE:CAH ) Q4 2022 Earnings Conference Call August 11, 2022 8:30 AM ET Company Participants Kevin Moran - VP, IR Michael Kaufmann - CEO & Director Jason Hollar - CFO Conference Call Participants Lisa Gill - JPMorgan Chase & Co. George Hill - Deutsche Bank Michael Cherny - Bank of America Merrill Lynch Steven Valiquette - Barclays Bank Eric Percher - Nephron Research Charles Rhyee - Cowen and Company Rivka Goldwasser - Morgan Stanley Kevin Caliendo - UBS Elizabeth Anderson - Evercore ISI Operator Good day, and welcome to the Fourth Quarter and Full Year 2022 Cardinal Health Inc. Earnings Conference Call. Today's conference is being recorded.

Cardinal Health, Inc. (CAH) CEO Michael Kaufmann on Q4 2022 Results - Earnings Call Transcript

Cardinal Health's (CAH) fiscal fourth-quarter results benefit from a solid performance in the Pharmaceutical segment.

Cardinal Health (CAH) Q4 Earnings Lag Estimates, Revenues Top

Cardinal (CAH) delivered earnings and revenue surprises of -10.26% and 5.62%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Cardinal Health (CAH) Lags Q4 Earnings Estimates

News for Cardinal Health Stock (CAH)